Overview of Ics Eus 2025 Abstract 166 Effects Of Glp 1 Receptor Agonists

Abstract Hypothesis / aims of study Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) are increasingly used for metabolic disorders; however, their effects on male reproductive hormones and semen quality remain insufficiently characterized.

Interpretation of results The results suggest that GLP-1 receptor agonists improve male reproductive endocrine function, particularly in obese and metabolically compromised men. Treatment with GLP -1RAs led to increases in total testosterone concentrations and favorable changes in gonadotropin secretion, notably with liraglutide.
Adverse effects of GLP

Abstract Background Glucagon-like peptide-1 receptor agonists ( GLP -1RAs) have transformed the management of type 2 diabetes and obesity by enhancing glycemic control, facilitating weight reduction, and diminishing cardiovascular risk. But as more people use them, there is increased interest in understanding the side effects and monitoring them.
Abstract Objective This debate paper aims to examine the effects of glucagon-like peptide-1 receptor agonists ( GLP-1 RAs), whose use in obesity and diabetes management has rapidly expanded, on fertility, contraceptive efficacy, and pregnancy outcomes in reproductive-aged individuals, and to provide evidence-based clinical guidance.

(PDF) Adverse effects of GLP
Adverse effects of GLP - 1 Receptor Agonists . Journal of Education, Health and Sport. 2025;78:57774 eISSN 2391 -8306.
The glucagon-like peptide-1 ( GLP-1 ) receptor agonists ( GLP -1RAs) are a class of medications primarily developed for the management of type 2 diabetes (T2D) and are increasingly being used for various other health effects .

Overview of Ics Eus 2025 Abstract 166 Effects Of Glp 1 Receptor Agonists
Purpose of Review The aim of the review is to evaluate the benefits and limitations of GLP-1 receptor agonists , with particular emphasis on adverse effects , unresolved safety issues, and the socioeconomic and ethical aspects of their growing popularity. Recent Findings Glucagon-like peptide-1 receptor agonists ( GLP-1 RAs) have transformed the management of type 2 diabetes mellitus (T2DM) and ...
Glucagon-like peptide 1 ( GLP-1 ), an incretin hormone primarily secreted by L-cells in the gut, prompts insulin release, thus reducing blood sugar levels and causing weight loss by inducing feelings of fullness while curbing appetite. GLP-1 receptor agonists ( GLP-1 RAs) mimic its effects , proving highly effective in managing type 2 diabetes mellitus (T2DM) and facilitating weight loss. While ...

Comprehensive evaluation of GLP
This umbrella review synthesizes the evidence for safety and efficacy GLP-1 receptor agonists on multiple outcomes including but not limited to metabolic, cardiovascular and renal outcomes.









Many Facets of GLP-1 Receptor Agonist Drugs Endocrine Society journals have published research articles and expert commentary on these important new medicines for years. This Thematic Issue includes a selection of our latest articles, published in our primary research journals since the start of 2024. These papers explore the multifaceted role of GLP-1 receptor agonist drugs in the treatment ...